{"id":"NCT03406104","sponsor":"GenSight Biologics","briefTitle":"RESCUE and REVERSE Long-term Follow-up","officialTitle":"Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials (RESTORE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-01-09","primaryCompletion":"2022-07-04","completion":"2022-07-04","firstPosted":"2018-01-23","resultsPosted":"2024-01-25","lastUpdate":"2025-09-09"},"enrollment":62,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Leber Hereditary Optic Neuropathy"],"interventions":[{"type":"GENETIC","name":"GS010","otherNames":["Lenadogene Nolparvovec"]},{"type":"OTHER","name":"Sham Intravitreal Injection","otherNames":[]}],"arms":[{"label":"GS010-treated Eyes","type":"EXPERIMENTAL"},{"label":"Sham-treated Eyes","type":"SHAM_COMPARATOR"}],"summary":"The goal of this clinical trial is to assess the long-term safety and efficacy of GS010, a gene therapy, and assess the quality of life in subjects with LHON due to the G11778A ND4 mitochondrial mutation and who were treated in the Rescue or Reverse studies.","primaryOutcome":{"measure":"Ocular Adverse Events (AEs)","timeFrame":"from year 2 to year 5 post treatment","effectByArm":[{"arm":"GS010 Treated Eyes","deltaMin":5,"sd":null},{"arm":"Sham Treated Eyes","deltaMin":1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"15 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":7,"countries":["United States","France","Germany","Italy","United Kingdom"]},"refs":{"pmids":["39699886","36449262","34108929"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":62},"commonTop":["Cataract","Gamma-Glutamyltransferase Increased","Intraocular Pressure Increased","Covid-19"]}}